Haemostatic trends in HIV-infected individuals in Yaoundé, Cameroon: a pilot study.
Haemostatic trends in HIV-infected individuals in Yaoundé, Cameroon: a pilot study.
复制标题
喀麦隆雅温得 HIV 感染者的止血趋势：一项试点研究。
DOI：
10.1097/mbc.0000000000000066
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Mbanya,Dora
中科院分区：
文献类型：
--
作者：
Tene,Larissa;Tagny,ClaudeT;Mintya-Ndoumba,Annick;Fossi,VictorN;Mbanya,Dora
Bleeding disorders are haematological manifestations that are frequently observed during HIV infection. This study intends to describe the haemostatic trends in HIV-infected patients in Cameroon. This cross-sectional descriptive study was carried out at the haematology unit of the Yaoundé University Teaching Hospital from March to June 2012. It included consenting HIV-positive patients, aged 18 years and above, naive to antiretroviral treatment or not. The coagulation profile was measured with Stago reagents (Stago Diagnostics, Asnières sur Seine, France) using a chronometric technique on a semi-automate (Stago Diagnostics). Platelets count was estimated on a human count automate (Human Diagnostics, Wiesbaden, Germany) by flow cytometry. A total of 139 HIV-infected patients were included in this study, out of which 106 were females (76.3%) against 33 (23.7%) males, giving a sex ratio of 0.3 (M/F). Mean age was 38.85 years (range 22–73 years) and median CD4 count was 353 cells/μl (Interquartile range 200–500 cells/μl). Hyperfibrinogenaemia was the most frequent bleeding disorder in the studied population [40 of 139 (28.78%)], followed by low prothrombin time (PT)[22 of 139 (15.83%)], thrombocytopenia [19 of 139 (13.67%)], hypofibrinogenaemia [18 of 139 (12.95)], prolonged activated partial thromboplastin time (7.91) and by thrombocytosis which was less frequent [6 of 139 (4.32%)]. Out of the six haemostatic disorders, only low PT was significantly associated with CD4 count (P= 0.02). This study showed that bleeding disorders are very frequent in the HIV-infected patients studied. Low PT was significantly associated with CD4 count, hence it may be recommended to systematic screen for bleeding disorders in severe immune-depressed (CD4≤ 200 cells/μl) HIV-infected patients.
